Holen Sie sich die Stockscreener-App
13.77
2.20%
-0.31
Handel nachbörslich:
13.67
-0.10
-0.73%
Schlusskurs vom Vortag:
$14.08
Offen:
$14.13
24-Stunden-Volumen:
178.86K
Relative Volume:
0.84
Marktkapitalisierung:
$157.35M
Einnahmen:
$26,600
Nettoeinkommen (Verlust:
$-14.73M
KGV:
-2.0187
EPS:
-6.8211
Netto-Cashflow:
$-8.76M
1W Leistung:
+20.58%
1M Leistung:
+4.64%
6M Leistung:
+37.84%
1J Leistung:
+52.15%
1-Tages-Spanne:
$13.77
$14.33
1-Wochen-Bereich:
$11.26
$14.97
52-Wochen-Spanne:
$4.86
$17.40
Kazia Therapeutics Limited Adr Stock (KZIA) Company Profile
Firmenname
Kazia Therapeutics Limited Adr
Sektor
Branche
Telefon
01161298780088
Adresse
140 WICKS RD, NEW SOUTH WALES 2113, NSW
Compare KZIA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KZIA
Kazia Therapeutics Limited Adr
|
13.77 | 160.89M | 26,600 | -14.73M | -8.76M | -6.8211 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kazia Therapeutics Limited Adr Stock (KZIA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | Laidlaw | Buy |
| 2025-02-06 | Eingeleitet | Maxim Group | Buy |
| 2021-10-14 | Eingeleitet | Maxim Group | Buy |
| 2021-01-05 | Eingeleitet | H.C. Wainwright | Buy |
Kazia Therapeutics Limited Adr Aktie (KZIA) Neueste Nachrichten
KZIA News | KAZIA THERAPEUTICS-SPON ADR (NASDAQ:KZIA) - ChartMill
Kazia Therapeutics (KZIA) director details existing ADS option grants - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) registers 10.7M ADS; names new CFO - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) registers 232,956 ADSs; names new CFO - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) registers 266,666 ADS; names new CFO - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) registers 95,110 ADSs; names new CFO - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) appoints James Levine as new CFO - Stock Titan
Kazia Therapeutics Appoints James Levine as Chief Financial Officer - Benzinga
Kazia Therapeutics (NASDAQ: KZIA) holder reports 18.5% stake in ADS - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) expands Phase 1b trial, enrollment to 36 patients - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) expands Paxalisib Phase 1b, files prospectus - Stock Titan
Kazia (NASDAQ: KZIA) expands Phase 1b, registers 266,666 ADSs - Stock Titan
Paxalisib breast cancer trial triples size at Kazia (NASDAQ: KZIA) - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) expands paxalisib trial; registers 10.7M ADS - Stock Titan
KZIA Stock Price, Quote & Chart | KAZIA THERAPEUTICS-SPON ADR (NASDAQ:KZIA) - ChartMill
Kazia Therapeutics (KZIA) Chief Scientific Officer Sudha Rao files initial Form 3 - Stock Titan
KZIA | Kazia Therapeutics Limited American Insider Trading - Quiver Quantitative
KZIA SEC FilingsKazia Therapeuti 10-K, 10-Q, 8-K Forms - Stock Titan
How Kazia Therapeutics Ltd (KZIA) Is Strengthening Its Team and Platform - Insider Monkey
Kazia (NASDAQ: KZIA) outlines cancer pipeline and runway to 2029 - Stock Titan
Dr. Sudha Rao joins Kazia Therapeutics (NASDAQ: KZIA) as part-time CSO - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) registers ADS and appoints Dr. Sudha Rao as CSO - Stock Titan
Kazia Therapeutics Expands Oncology Pipeline With SETDB1 Targeted Epigenetic Platform - BioPharma APAC
Kazia Therapeutics (NASDAQ: KZIA) in-licenses SETDB1 platform, pays $1.39M - Stock Titan
Kazia (NASDAQ: KZIA) licenses SETDB1 platform, plans $6M dual-program push - Stock Titan
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform - Bitget
Kazia adds AI-built cancer drug platform with lead candidate MSETC - Stock Titan
Kazia Therapeutics (KZIA) CEO updates ADS option exercise price details - Stock Titan
Kazia Therapeutics (KZIA) executive discloses multiple stock option positions - Stock Titan
95,110 ADS supplement and director exit — Kazia (NASDAQ: KZIA) - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) holder reports 1.59M ADS; 13.90% stake - Stock Titan
Alumni Capital exits KZIA holdings (KZIA) — 0 ADS as of Jan 30, 2026 - Stock Titan
Kazia Therapeutics (KZIA) widens loss yet amasses $69.5m cash and new ATM - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) registers 10.7M ADSs, reports $69.46M cash - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) registers 266,666 ADSs; posts half‑year update - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) files prospectus supplement for 232,956 ADSs - Stock Titan
Kazia Therapeutics (KZIA) raises major cash despite $12.6m loss - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) director Coffey details ADS options and share stakes - Stock Titan
Kazia Therapeutics (KZIA) CEO discloses multi-million share option stakes on Form 3 - Stock Titan
Kazia Therapeutics (KZIA) VP discloses initial ADS option grants - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) files $200M shelf; $100M ATM with Leerink - Stock Titan
Maxim Group Sticks to Its Buy Rating for Quoin Pharmaceuticals (QNRX) - The Globe and Mail
Jorey Chernett holds 12.46% of Kazia Therapeutics (KZIA) ADS - Stock Titan
Ikarian Capital discloses 5.1% Kazia Therapeutics (KZIA) ADS position - Stock Titan
Dauntless Investment trims Kazia Therapeutics (KZIA) position to negligible 0.0% - Stock Titan
Kazia Therapeutics stock rises on promising nuclear PD-L1 degrader data By Investing.com - Investing.com India
Kazia Therapeutics stock rises on promising nuclear PD-L1 degrader data - Investing.com UK
Experimental cancer drug targets hidden resistance driving metastasis - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) posts early TNBC trial gains in paxalisib study - Stock Titan
Early paxalisib TNBC responses highlighted by Kazia Therapeutics (NASDAQ: KZIA) - Stock Titan
Early paxalisib TNBC data: Kazia Therapeutics (NASDAQ: KZIA) sees partial and complete responses - Stock Titan
Finanzdaten der Kazia Therapeutics Limited Adr-Aktie (KZIA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):